🇺🇸 FDA

Company profile · Sponsor

Nektar

Nektar Therapeutics UK Limited

NKTR · NYSE pharma SAN FRANCISCO, CA, GB
Pipeline
24
Drugs
1
Patents
8

Quick answer

Nektar (NKTR) is a pharma company. headquartered in SAN FRANCISCO, CA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker NKTR
Exchange NYSE
Company type pharma
Headquarters SAN FRANCISCO, CA, GB
SEC CIK 0000906709

Pipeline (24)

Search pipeline →

  1. Amikacin Inhalation Solution (BAY41-6551)

    Nektar

    Pneumonia, Bacterial

    phase 3 small molecule completed

    1 trial

  2. Bempegaldesleukin

    Nektar

    Metastatic Head and Neck Cancer

    phase 3 small molecule terminated

    1 trial

  3. Bempegaldesleukin

    Nektar

    Melanoma

    phase 3 mab terminated

    1 trial

  4. Inhaled Human Insulin

    Nektar

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  5. NKTR-102

    Nektar

    Metastasis

    phase 3 small molecule completed

    1 trial

  6. NKTR-102

    Nektar

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  7. NKTR-181 BID tablets

    Nektar

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  8. NKTR-214

    Nektar

    Melanoma

    phase 3 mab completed

    1 trial

  9. NKTR-255 at 1.5 µg/kg

    Nektar

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  10. Nivolumab

    Nektar

    Bladder Cancer

    phase 3 mab completed

    1 trial

  11. bempegaldesleukin

    Nektar

    Renal Cell Carcinoma

    phase 3 mab terminated

    1 trial

  12. Amikacin (BAY41-6551)

    Nektar

    Pneumonia

    phase 2 small molecule completed

    1 trial

  13. Amikacin inhalation solution (BAY41-6551)

    Nektar

    Pneumonia

    phase 2 small molecule completed

    1 trial

  14. Avelumab

    Nektar

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  15. Bempegaldesleukin

    Nektar

    Urinary Bladder Neoplasm

    phase 2 mab completed

    1 trial

  16. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Nektar

    Melanoma

    phase 2 small molecule completed

    1 trial

  17. Dronabinol MDI

    Nektar

    Migraine With Aura

    phase 2 small molecule completed

    1 trial

  18. Etirinotecan pegol

    Nektar

    Anaplastic Astrocytomas

    phase 2 small molecule completed

    1 trial

  19. LY3471851

    Nektar

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    2 trials

  20. LY3471851

    Nektar

    Colitis, Ulcerative

    phase 2 small molecule terminated

    1 trial

  21. NKTR-102

    Nektar

    Tumor

    phase 2 small molecule completed

    1 trial

  22. NKTR-102

    Nektar

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. NKTR-102 100 mg/m2

    Nektar

    Tumor

    phase 2 small molecule completed

    1 trial

  24. NKTR-102 145 mg/m2

    Nektar

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. etirinotecan pegol

    ONZEALD

    L01

Patents (8)

Search patents →

  1. US 12324828

    Conjugates of a factor VIII moiety having an oxime-containing linkage

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12325708

    Adenosine 2 receptor antagonists

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12247059

    Conjugates of an IL-2 moiety and a polymer

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12233104

    Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12214045

    Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12054553

    Immunotherapeutic tumor treatment method

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12030940

    Immunotherapeutic tumor treatment method

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Nektar?

Nektar (NKTR) is a pharma company. headquartered in SAN FRANCISCO, CA, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Nektar sponsor?

We track 24 ClinicalTrials.gov-linked programs for Nektar, including Amikacin Inhalation Solution (BAY41-6551) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Nektar company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.